New Biopharma IPOs Show Modest Step Up In Step-Ups
This article was originally published in Start Up
Executive Summary
The IPO drumbeat for drug companies is slow but steady, with valuations looking a bit stronger than 2011. But insider participation, haircuts and dilution are still the order of the day.
You may also be interested in...
For Biotech VCs, Anticipation And Adjustments In The Age Of Earn-Outs
The structured acquisition -- with contingent payments that stretch well beyond the close of the sale – is a permanent part of the biotech investor landscape. While it's certainly a buyer's market, the sellers have been adapting to help boost returns. Are their strategies working?
Supernus Pharmaceuticals Inc.
In the early part of this decade, Shire Laboratories was the engine that drove much of Shire PLC's success. The drug delivery unit, which specialized in oral formulations, played a key role in developing many of Shire's top products. Those technologies, as well as existing partnerships, now reside at Supernus Pharmaceuticals, which intends to turn Shire's former drug delivery business into a fully integrated, CNS-focused specialty pharmaceuticals firm.
The Biopharma A List: Taking The Pulse Of Newco Creation
On the new company creation front, using Series A financings as a proxy, start-ups have not escaped the challenging funding environment. Here we update trends in those first-time rounds for 2023.